Trial Profile
Impact of Chronic Kidney Disease on the Pharmacodynamic and Pharmacokinetic Effects of Ticagrelor in Patients With Diabetes Mellitus and Coronary Artery Disease
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jan 2022
Price :
$35
*
At a glance
- Drugs Ticagrelor (Primary)
- Indications Coronary artery disease
- Focus Therapeutic Use
- 15 Sep 2020 Status changed from active, no longer recruiting to completed.
- 23 Jun 2020 Planned End Date changed from 1 May 2020 to 1 Aug 2020.
- 02 Mar 2020 Planned End Date changed from 1 Feb 2020 to 1 May 2020.